GGI
SUPN icon

Godsey & Gibb Inc’s Supernus Pharmaceuticals SUPN Stock Holding History

Godsey & Gibb Inc’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$3.62K – 403
2024
Q4 		$3.62K Hold
100
– – ﹤0.01% 320
2024
Q3 		$3.12K Buy
+100
New +$3.12K ﹤0.01% 388

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Godsey & Gibb Inc's SUPN Position: Q1 2025 in Review

Godsey & Gibb Inc sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 100 shares — an estimated $3.62K sold.

Godsey & Gibb Inc first reported a position in SUPN in Q3 2024 and held it in 2 quarters. The position peaked at $3.62K in Q4 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Godsey & Gibb Inc reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Godsey & Gibb Inc sold 100 Supernus Pharmaceuticals shares in Q1 2025, an estimated $3.62K.
  • Godsey & Gibb Inc first reported a position in Supernus Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Godsey & Gibb Inc's Supernus Pharmaceuticals position peaked at $3.62K in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Godsey & Gibb Inc's 13F filing for Q1 2025, filed 11 Apr 2025.